Usually when we debate whether a stock is expensive or cheap, we’re referring to its valuation, or how much you’re paying per share for future earnings.
Hot Sliver Companies To Buy For 2015: Macy’s Inc (M)
Macy�s, Inc., together with its subsidiaries, operates stores and Internet Websites in the United States. Its retail stores and Internet Web sites sell a range of merchandise, including apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates Bloomingdale�s Outlet stores that offer a range of apparel and accessories, including ready-to-wear, shoes, fashion accessories, jewelry, handbags, and intimate apparel products. As of January 28, 2012, it operated approximately 840 stores under the names of Macy�s and Bloomingdale�s; and 7 Bloomingdale�s Outlet stores, as well as macys.com and bloomingdales.com. The company was formerly known as Federated Department Stores, Inc. and changed its name to Macy�s, Inc. in June 2007. Macy�s, Inc. was founded in 1820 and is based in Cincinnati, Ohio.Advisors' Opinion:
- [By Ben Levisohn]
Morgan Stanley’s�Kimberly Greenberger and�Duo Li�explain why they declared�Macy’s�(M) a Best Idea:Getty Images�
Consistent execution, clear EPS growth algorithm, sector-leading FCF yield and shareholder returns deserve a higher FY2 P/E multiple than 12x…
- [By Damian Illia]
Guess markets its products through a wide brand portfolio and, through six store concepts, the company operates as much as 512 locations in the US and 1,178 internationally, 858 of which are licensees. Its U.S. wholesale customers are large department stores like Macy�� Inc. (M), and Bloomingdale��.
- [By Steve Symington]
Meanwhile, as fellow Fool Andrew Marder just pointed out, competitors Nordstrom (NYSE: JWN ) and Macy's (NYSE: M ) have remained solidly profitable, and both just posted comparable-store sales increases of 0.8% and 3.8%, respectively. Macy's, for its part, even saw earnings per share rise 28% year over year during its most recent quarter. In addition, both Macy's and Nordstrom sport reasonable price-to-earnings ratios below 17, and they offer solid 2% dividends to keep long-term investors happy.
- [By Rich Duprey]
Yet the service does set Kmart apart from some of its top rivals, such as Target (NYSE: TGT ) , which offers only a standard free shipping option if you use your Target credit card for the purchase. Macy's (NYSE: M ) doesn't offer it at all.
Top 5 Warren Buffett Stocks To Buy Right Now: TSR Inc.(TSRI)
TSR, Inc., together with its subsidiaries, provides contract computer programming services to commercial customers, and state and local government agencies in the metropolitan New York area, New England, and the mid-Atlantic region. It offers technical computer personnel to supplement in-house information technology capabilities. The company provides its staffing services in the areas of mainframe and mid-range computer operations, personal computers and client-server support, Internet and e-commerce operations, voice and data communications, and help desk support capabilities. TSR, Inc. was founded in 1969 and is based in Hauppauge, New York.Advisors' Opinion:
- [By Geoff Gannon] ay.
TSRI is typical of the kinds of net-nets you find on this list. The number of net-nets with five straight years of profits is about a dozen stocks. TSR is one of them. It is controlled by the founder. He formed the company 42 years ago. And he still owns 46% of the company today.
Other companies on the list of profitable net-nets also involve one man (or one family) control. These include:
路 Micropac (MPAD)
路 ADDvantage Technologies (AEY)
路 Solitron Devices (SODI)
路 OPT-Sciences (OPST)
Micropac is 76% owned by Heinz-Werner Hempel. He�� a German businessman. You can see the German company he founded here. He�� had control of Micropac for a long-time. I don�� have an exact number in front of me. But I would guess it�� been something like 25 years.
ADDvantage Technologies is controlled by the Chymiak brothers. See the company�� April 4 press release explaining their decision to turn over the CEO position to an outsider. Regardless, the Chymiaks still control 47% of the company. Ken Chymiak is now chairman. And David Chymiak is still a director and now the company�� chief technology officer. Clearly, it�� still their company.
By the way, the name ADDvantage Technologies has nothing to do with the Chymiaks. Today�� AEY really traces its roots to a private company called Tulsat. The Chymiak brothers acquired that company about 27 years ago. So, effectively, when you buy shares of AEY you are buying into a 27-year-old family-controlled company.
That�� pretty typical in the world of net-nets.
Solitron Devices is 29% owned by Shevach Saraf. He has been the CEO for 20 years. The post-bankruptcy Solitron has never known another CEO. Before the bankruptcy, Solitron was a much bigger, much different company. So even though we are not talking about the founder here ��and even though 70% of the company�� shares are not held by the CEO
Top 5 Warren Buffett Stocks To Buy Right Now: Cedar Fair L.P. (FUN)
Cedar Fair, L.P. owns and operates amusement and water parks in the United States and Canada. As of February 19, 2013, the company operated 11 amusement parks, 4 outdoor water parks, 1 indoor water park, and 5 hotels, as well as the Gilroy Gardens Family Theme Park in California under a management contract. Its amusement parks include Cedar Point located on Lake Erie between Cleveland and Toledo in Sandusky, Ohio; Kings Island near Cincinnati, Ohio; Canada's Wonderland near Toronto, Canada; Dorney Park & Wildwater Kingdom located near Allentown in South Whitehall Township, Pennsylvania; Valleyfair located near Minneapolis/St. Paul in Shakopee, Minnesota; Michigan's Adventure located near Muskegon, Michigan; Kings Dominion near Richmond, Virginia; Carowinds in Charlotte, North Carolina; Worlds of Fun located in Kansas City, Missouri; Knott's Berry Farm located near Los Angeles in Buena Park, California; and California's Great America located in Santa Clara, California, as w ell as manages and operates Gilroy Gardens Family Theme Park in Gilroy, California. The company also owns and operates the Castaway Bay Indoor Waterpark Resort in Sandusky, Ohio. Cedar Fair Management, Inc. serves as the general partner of Cedar Fair, L.P. The company was founded in 1983 and is based in Sandusky, Ohio.Advisors' Opinion:
- [By James E. Brumley]
On the battlefield, you can always tell when the commanding officer is close to beginning a major assault when he starts to move pieces of military hardware around to maximize their effectiveness in light of the battle plan. The same idea applies in the business world - when personnel additions are made, and people are moved around, it's usually the beginning of something big. That's why investors may want to prep themselves for something big from Independent Film Development Corporation (OTCMKTS:IFLM). The company placed a new CEO today after naming a CFO last week, and moved the previous CEO over to the lead role of real estate operations [which was always the plan]. So what? All these changes are an omen that IFLM is finally ready to begin its frontal assault on the likes of amusement park names such as Cedar Fair, L.P. (NYSE:FUN), or even against the venerable The Walt Disney Company (NYSE:DIS). But nobody beats Walt Disney at its own game, you say? We'll see.
Top 5 Warren Buffett Stocks To Buy Right Now: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.Advisors' Opinion:
- [By Selena Maranjian]
Among holdings in which Soros Fund Management increased its stake was Sarepta Therapeutics (NASDAQ: SRPT ) . Sarepta has seen its stock soar more than eightfold over the past year, and some still see it as undervalued. Its stock fell a while back on news that after Sarepta petitioned the FDA for accelerated approval for its Duchenne muscular dystrophy drug, eteplirsen, the FDA requested more information.�Management is optimistic about its recent interactions with the FDA, though.
- [By Rich Bieglmeier]
It's not every day that a stock is up 40% but still might have another 50%+ to go. However, that is the case with Sarepta Therapeutics Inc. (NASDAQ:SRPT).